Chemomab Therapeutics Ltd (CMMB) - News Archive

Abstract: Chemomab Therapeutics Ltd. recently announced its financial results for the fourth quarter and the year ended 2024, revealing mixed outcomes regarding its performance relative to competitors in the pharmaceuti...

Unlocking New Frontiers in Primary Sclerosing Cholangitis: The Promise of Chemomabs CM-101 Recent research presented at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2024 has showcas...

Chemomab Therapeutics: Q3 2024 Financial Results and Corporate Progress Highlights Chemomab Therapeutics, a clinical-stage biotechnology company focused on developing innovative therapeutics for fibrotic and inflammator...

Chemomab Therapeutics Announces Closing of $10 Million Private PlacementRecently, Chemomab Therapeutics Ltd announced the successful closing of a $10 million private placement financing round that included both new and...

In a move that underscores Chemomab Therapeutics commitment to its groundbreaking research and development activities, the biotech firm recently announced the successful completion of a $10 million Private Investment in...

Chemomab Therapeutics has recently made significant strides in the quest for effective treatments for fibrotic diseases, particularly Primary Sclerosing Cholangitis (PSC) and systemic sclerosis. The company has released...

Chemomab Therapeutics has recently published two significant articles that highlight the clinical potential of their CCL24-neutralizing antibody, CM-101. These publications reinforce the role of CCL24 in primary scleros...

Novel Therapeutic Approach for Primary Sclerosing Cholangitis: CM-101 Shows Promise in Clinical Data Presented by Chemomab Therapeutics Chemomab Therapeutics is making waves in the field of hepatology with its innovativ...

Chemomab Receives 180-Day Extension to Regain Compliance with Nasdaq Listing RequirementsChemomab, a biopharmaceutical company focused on developing novel antibodies for the treatment of inflammatory and fibrotic diseas...

Systemic sclerosis is characterized by the abnormal production and accumulation of collagen, leading to fibrosis and tissue damage. The disease often progresses slowly but can cause significant disability and impact the...

In a significant development, Chemomab has been granted a new European patent for its groundbreaking monoclonal antibody, CM-101. This patent extension further strengthens Chemomab s intellectual property portfolio in s...